Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06365060
Recruiting
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Not applicable · United States · 13 sites
Registry update: 26 Oct 2026
NCT06497738
Recruiting
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
Not applicable · China · 6 sites
Registry update: 17 Aug 2025
NCT06149910
Recruiting
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Not applicable · United States · 1 site
Registry update: 3 May 2024
NCT06182774
Recruiting
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Phase 3 · Canada · 31 sites
Registry update: 14 Oct 2026
2023-505775-70-00
Recruiting
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Phase 2 · Finland, France, Greece, Italy, Netherlands, Norway · 24 sites
Registry update: 3 Aug 2026
Conflicting statuses (not updated in the registry for 3 months)
NCT06189833
Recruiting
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
Phase 2 · Austria, Germany, Greece, Italy, Netherlands · 28 sites
Registry update: 4 Nov 2026
2023-507402-13-00
Recruiting
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
Phase 3 · Austria, Germany · 80 sites
Registry update: 9 Jul 2025
NCT06271252
Recruiting
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Phase 1 · United States · 1 site
Registry update: 2 Aug 2024
NCT06385652
Recruiting
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 16 Apr 2026
NCT06228794
Recruiting
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
Not applicable · China · 1 site
Registry update: 21 May 2025
NCT06279026
Recruiting
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Not applicable · China · 1 site
Registry update: 26 Feb 2024
NCT06103838
Recruiting
18F-Fluciclovine PET/CT in Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 10 Nov 2026
NCT06484829
Recruiting
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · China · 1 site
Registry update: 2 Apr 2025
NCT06297226
Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 · Australia, Canada, Japan, United States · 52 sites
Registry update: 6 Oct 2026
NCT06138275
Recruiting
Elranatamab in R/R Multiple Myeloma
Phase 2 · United States · 3 sites
Registry update: 31 Aug 2026
NCT05887167
Recruiting
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Phase 1 · United States · 1 site
Registry update: 10 Aug 2026
NCT06232096
Recruiting
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Phase 1/2 · China · 1 site
Registry update: 15 Mar 2024
NCT06121843
Recruiting
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 · Canada, United States · 19 sites
Registry update: 16 Jul 2026
NCT05896228
Recruiting
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 11 Mar 2026
NCT05836896
Recruiting
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Phase 1 · Germany · 1 site
Registry update: 27 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.